Medical Scientist
Dr. rer. nat. Ivana Paskov-Skapik
Department of General, Visceral, Transplantation and Thoracic Surgery
Research Focus: Developing novel therapeutic strategies for colorectal cancer (CRC)
Contact: paskovskapik@med.uni-frankfurt.de
Member of the Wiegering Lab
To explore the potential of diminishing the elevated transcriptional activity of the RNAPOL1 machinery as a therapeutic strategy for colorectal cancer (CRC), Dr. Ivana Paskov-Skapik employs the established RNAPOL1 inhibitor CX5461. Treatment with CX5461 results in transcription-replication conflicts (TRC) and triggered a DNA damage response (DDR) in CRC cells. Therefore, the research group proposes that combining CX5461 with DDR checkpoint inhibition may produce synergistic effects. Using the colorectal liver metastasis (CRLM) mouse model, the Wiegering Lab aims to determine the most effective therapeutic strategy and confirm the efficacy of the RNAPOL1 inhibitor CX5461 in conjunction with the DDR inhibition in vivo.
